The addition of TrialMaster EDC is intended to streamline the study development process and increase the efficiency of trials. Budget cuts at pharma and lack of biotech funding mean that contract research organisations (CRO) must pay close attention to the efficiency of operations.
Kendle believes TrialMaster EDC can help it achieve this. John Fontenault, the company’s global head, clinical data management and technology, explained the deal supports the company’s “focus on providing our global biopharmaceutical customers with cost-effective access to the best eClinical solutions to accelerate their Phase I through IV clinical trials”.
The CRO has conducted more than 250 trials using EDC technologies, according to Stephen Johnson, chief operating officer of OmniComm, who believes use of TrialMaster will allow Kendle to deliver “best-in-class clinical development services” to its customers.
TrialMaster offering
TrialMaster allows the user to easily and securely collect, validate, transmit and analyse clinical trial data, including patient histories, dosing and adverse events, according to OmniComm.
The company claims the EDC technology can shorten the time to complete a study, reduce expenditure on integration projects and improve communication across multiple business units.
At the start of September three organisations joined OmniComm’s CRO Preferred Program which gives clients TrialMaster at a fixed price with complete sales and marketing support. After the addition of the three clients OmniComm claimed to have almost 40 CRO partners.
Johnson added: “Partnering with OmniComm allows CROs to offer their customers a first class EDC product and gives them a competitive edge in the bidding process. It’s a win for everyone involved, the CRO, OmniComm and most importantly the clients that we serve."